William Blair Comments on Amgen's Q3 Earnings (NASDAQ:AMGN)

Key Points

• William Blair has revised its Q3 2025 earnings per share estimate for Amgen, lowering it from $5.40 to $4.20, while maintaining an "Outperform" rating on the stock.
• Amgen reported a Q2 earnings per share of $6.02, exceeding analysts' expectations and marking a year-over-year revenue increase of 9.4% to $9.18 billion.
• The company announced a quarterly dividend of $2.38, giving an annualized yield of 3.3%, with a dividend payout ratio currently at 77.84%.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Stock analysts at William Blair lowered their Q3 2025 earnings estimates for shares of Amgen in a report issued on Wednesday, August 6th. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings of $4.20 per share for the quarter, down from their previous forecast of $5.40. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen's Q4 2025 earnings at $5.74 EPS, Q1 2026 earnings at $5.41 EPS, Q2 2026 earnings at $5.96 EPS, Q3 2026 earnings at $5.16 EPS and Q4 2026 earnings at $6.05 EPS.

A number of other analysts have also commented on the stock. Citigroup boosted their price target on shares of Amgen from $305.00 to $310.00 and gave the company a "neutral" rating in a research note on Wednesday. Cantor Fitzgerald restated a "neutral" rating and set a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. Mizuho boosted their price target on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, May 7th. Piper Sandler reiterated an "overweight" rating and issued a $328.00 target price on shares of Amgen in a research note on Friday, June 27th. Finally, UBS Group reduced their target price on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $303.76.

Amgen Stock Up 1.2%

AMGN stock traded up $3.53 during midday trading on Friday, reaching $288.23. 1,802,960 shares of the company's stock traded hands, compared to its average volume of 2,050,777. The company has a market cap of $155.17 billion, a price-to-earnings ratio of 23.57, a P/E/G ratio of 2.47 and a beta of 0.49. The firm's fifty day moving average price is $293.23 and its 200-day moving average price is $292.71. The company has a quick ratio of 0.88, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen has a 52 week low of $253.30 and a 52 week high of $339.17.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. The business had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen's quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.97 EPS.

Institutional Investors Weigh In On Amgen

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Amgen by 0.3% during the first quarter. Vanguard Group Inc. now owns 52,870,453 shares of the medical research company's stock worth $16,471,790,000 after acquiring an additional 148,658 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Amgen by 2.3% during the second quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company's stock worth $3,619,489,000 after acquiring an additional 291,271 shares in the last quarter. Capital International Investors raised its stake in shares of Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after acquiring an additional 3,495,503 shares in the last quarter. Capital World Investors raised its stake in shares of Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after acquiring an additional 6,029,058 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Amgen by 15.8% during the fourth quarter. Northern Trust Corp now owns 6,431,029 shares of the medical research company's stock worth $1,676,183,000 after acquiring an additional 875,254 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.76% of the stock is currently owned by insiders.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be given a dividend of $2.38 per share. The ex-dividend date is Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.3%. Amgen's payout ratio is presently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.